This article, published in the October issue of the Journal of Clinical Oncology, describes the first study of the antigastrin immunogen G17DT in pancreatic cancer.
In the study, a team of researchers sought to determine the antibody response, safety, tolerability, and preliminary evidence of efficacy of G17DT in advanced pancreatic cancer.
The team immunized 30 patients with advanced pancreatic cancer with 3 doses of either 100 µg or 250 µg of G17DT.
In the whole group, 67% of the patients produced an antibody response.
|Patient response rate:|
- 250-µg dose = 82%
- 100-µg dose = 46%
|Journal of Clinical Oncology|
The researchers found that the 250-µg dose resulted in a response rate of 82%, significantly greater than that for the 100-µg group (46%).
They identified the most significant side effects, seen in 3 patients, as local abscess and/or fever.
The median survival for the whole group, from the date of the first immunization, was 187 days. However, the median survival was 217 days for the antibody responders, but only 121 days for the antibody nonresponders.
This difference in survival between the antibody responders and nonresponders was found to be significant (p = 0.0023).
Dr Caplin's team concluded that, "Patients with advanced pancreatic cancer are able to mount an adequate antibody response to G17DT".
"The 250-µg dose is superior to the 100-µg dose, and it appears to be generally well tolerated.
"Antibody responders demonstrate significantly greater survival than antibody nonresponders".